Perrigo Company Stock PRGO
Perrigo is a consumer self-care company that develops, manufactures, and markets over-the-counter health and wellness products, primarily under store brand (private label) and licensed brand formats. Perrigo Company stock (PRGO): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Perrigo Company stock (PRGO): listed on NYSE. NadirAlpha has evaluated 47 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Revenue Q2 2026: USD 1 billion (-3% year on year). Latest reported (Q2 2026): Total Debt, Net Leverage, Net Interest Expense. Latest reading: Operating income turned positive, Net income turned positive, EBITDA turned positive, Guidance confirmed, Strategic pivot, Divestiture.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Perrigo Company Current Status
The current state of Perrigo Company at a glance, figures as of Q2 2026, with core figures and the key management statements from the latest filing. NadirAlpha methodology
Assessment by NadirAlpha, as of Q2 2026.
“Looking ahead, we are reaffirming our full-year 2026 outlook with a sequentially stronger second half, supported by clear and tangible drivers, including the expected moderation of planned under absorption stemming from lower prior-year sales volumes, more favorable category comparisons, and continued strong operational execution. While mindful of an uncertain consumer and macroeconomic environment, we are continuing to gain market share, streamline our portfolio, and strengthen our balance sheet. At the same time, we remain focused on converting our operational progress into sustainable growth and long-term shareholder value.”
“We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt. While results were impacted by ongoing category softness and macroeconomic headwinds, we again drove market share gains as our broad portfolio of quality self-care products across all price points continues to resonate with consumers seeking value and affordability. We also took another important step in simplifying our portfolio by completing the previously announced sale of our Dermacosmetics business, and are continuing the strategic reviews of our Infant Formula and Oral Care businesses. We are becoming a more focused consumer self-care company, and are making progress in strengthening the underlying fundamentals of our business.”
Perrigo Company Stock: Key Figures ($ million)
Revenue, margin, earnings and EPS of Perrigo Company per fiscal year, half-year and quarter in $ million, as of Q2 2026, as reported in the filing; restatements show the most recent filing version. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | OCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 4,253.1 | -1,122.2 | 622.3 | -1,425.4 | -10.29 | 2.75 | 238.5 | 26 |
| FY2024 | 4,373.4 | 112.9 | 318.7~ | -171.8 | -1.25 | 2.57 | 362.9 | 18 |
| FY2023 | 4,655.6 | 151.9 | 285.2 | -12.7 | -0.09 | 2.58 | 405.5 | 9 |
Quarters
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | EBITDA (adj.) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-05 | 1,022.8 | 23.5 | 125 | 74.5 | 0.53 | – | – | 68.3 | 399.7 | 2,895.1 | 30 |
| 2026-Q1* | 2026-05-06 | 969.2 | -372.3 | 113 | -398.6 | -2.87 | 0.43 | – | -127.4 | 357.2 | 12.4~ | 28 |
| 2025-Q4* | 2026-02-26 | 1,109.6 | -1,287.2 | 167.2 | -1,418.1 | -10.24*≈ | 0.77 | – | 148.6 | 531.6 | 75.4~ | 126 |
| 2025-Q3* | 2025-11-05 | 1,043.3 | 72.6 | 173.4 | 7.5 | 0.05 | 0.80 | – | 29.8 | 432.1 | 50.9~ | 23 |
| 2025-Q2* | 2025-08-06 | 1,056.3 | 45.4 | 135.2 | -8.4 | -0.06 | 0.57 | – | 56.7 | 454.2 | 115.8~ | 21 |
| 2025-Q1* | 2025-05-07 | 1,043.9 | 46.9 | 146.6 | -6.4 | -0.05 | 0.60 | – | -90 | 409.9 | 25.7~ | 19 |
| 2024-Q4* | 2025-02-27 | 1,138.3 | 114.2 | 83.4~ | -44.5 | -0.32*≈ | 0.93 | – | 274.9 | 558.8 | -78.8~ | 17 |
| 2024-Q3* | 2024-11-06 | 1,087.5 | 80.4 | 91.9~ | -21 | -0.15 | 0.81 | – | 15.1 | 1,463.5 | -115.9~ | 15 |
| 2024-Q2* | 2024-08-02 | 1,065.5 | -26.5 | 90.7~ | -108.4 | -0.79 | 0.53 | – | -18.9 | 542.8 | 96.8~ | 13 |
| 2024-Q1* | 2024-05-07 | 1,082.1 | -55.2 | 52.7~ | 2 | 0.01 | 0.29 | – | -26.5 | 658.5 | 3,407 | 11 |
| 2023-Q4* | 2024-02-27 | 1,156.9 | -15.5 | 65.1~ | -32.3 | -0.24*≈ | 0.86 | 460.3 | 181.9 | 751.3 | 77.5~ | 9 |
| 2023-Q3* | 2023-11-07 | 1,123.8 | 62.1 | 79.7~ | 14.2 | 0.10 | 0.64 | – | 92.9 | 598.3 | 54.7~ | 108 |
| 2023-Q2* | 2023-08-08 | 1,193.1 | 56.8 | 70.1~ | 8.4 | 0.06 | 0.63 | – | 32.9 | 555.2 | 24~ | 5 |
| 2023-Q1* | 2023-05-09 | 1,181.7 | 48.5 | 70.3~ | -3 | -0.02 | 0.45 | – | -3.8 | 553 | -19.4~ | 3 |
Perrigo Company Balance Sheet & Cash Flow ($ million)
NadirAlpha places cash, debt, operating cash flow and investments of Perrigo Company side by side per period, balance sheet values as of the period end, flow items for the period. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-26 | 531.6 | 3,640.2 | 75.4~ | 337.5 | 238.5 | 93.4 | 145.1 | 25 |
| FY2024 | 2025-02-27 | 558.8 | 3,618.1 | -78.8~ | 325.9 | 362.9 | 118.3 | 244.6 | 17 |
| FY2023 | 2024-02-27 | 751.3 | 4,073.4 | 77.5~ | 359.5 | 405.5 | 101.7 | 303.8 | 9 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-05 | 399.7 | 3,294.8 | 2,895.1 | 95.9 | 82.6 | 14.3 | 68.3 | 30 |
| 2026-Q1 | 2026-05-06 | 357.2 | 3,632.5 | 12.4~ | 83.3 | -113.6 | 13.8 | -127.4 | 28 |
| 2025-Q4 | 2026-02-26 | 531.6 | 3,640.2 | 75.4~ | 85.9 | 175.4 | 26.8 | 148.6 | 126 |
| 2025-Q3 | 2025-11-05 | 432.1 | 3,644.7 | 50.9~ | 85.4 | 51.7 | 21.9 | 29.8 | 23 |
| 2025-Q2 | 2025-08-06 | 454.2 | 3,651.9 | 115.8~ | 86.3 | 75.9 | 19.2 | 56.7 | 21 |
| 2025-Q1 | 2025-05-07 | 409.9 | 3,627.5 | 25.7~ | 79.9 | -64.5 | 25.5 | -90 | 19 |
| 2024-Q4 | 2025-02-27 | 558.8 | 3,618.1 | -78.8~ | 80.3 | 312.6 | 37.7 | 274.9 | 17 |
| 2024-Q3 | 2024-11-06 | 1,463.5 | 4,753.3 | -115.9~ | 82.3 | 42.2 | 27.1 | 15.1 | 15 |
| 2024-Q2 | 2024-08-02 | 542.8 | 4,057.6 | 96.8~ | 81.9 | 9.5 | 28.4 | -18.9 | 13 |
| 2024-Q1 | 2024-05-07 | 658.5 | 4,065.5 | 3,407 | 81.4 | -1.4 | 25.1 | -26.5 | 11 |
| 2023-Q4 | 2024-02-27 | 751.3 | 4,073.4 | 77.5~ | 85.9 | 208.6 | 26.7 | 181.9 | 9 |
| 2023-Q3 | 2023-11-07 | 598.3 | 4,086.6 | 54.7~ | 91 | 124.7 | 31.8 | 92.9 | 108 |
| 2023-Q2 | 2023-08-08 | 555.2 | 4,094.3 | 24~ | 93.9 | 52.9 | 20 | 32.9 | 5 |
| 2023-Q1 | 2023-05-09 | 553 | 4,101.6 | -19.4~ | 88.7 | 19.4 | 23.2 | -3.8 | 3 |
Perrigo Company Guidance Tracking (latest per metric/period · 17/24)
All forecasts (guidance) of the Perrigo Company management and their later outcome: per metric and period the most recent statement applies, the status is checked against the reported actuals. NadirAlpha methodology
Actuals: revenue in $m · EPS in $ per share · ratios in %
Direction: confirmedcutinitiated Verdict: in linemisspending
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2028 | 2025-05-07 | Annual run-rate potential savings | 200–300 | – | 19 | ||
| FY2026 | 2026-08-05 | Gross margin (non-GAAP) | 36.5–37.5% | – | 31 | ||
| FY2026 | 2026-08-05 | Operating margin | 12.5–13.5% | – | 31 | ||
| FY2026 | 2026-08-05 | Revenue growth (YoY) | -5.5–-1.5% | – | 31 | ||
| FY2026 | 2026-08-05 | Core Net Sales Growth | -3–1% | – | 31 | ||
| FY2026 | 2026-02-26 | EPS (non-GAAP) | 2–2.3 | – | 31 | ||
| FY2026 | 2025-05-07 | Annualized pre-tax savings | 140–170 | – | 19 | ||
| FY2025 | 2025-11-05 | EPS (non-GAAP) | 2.7–2.8 | 2.75 | 24 | ||
| FY2025 | 2025-11-05 | Revenue growth (YoY) | -3–-2.5% | -2.8 | 24 | ||
| FY2025 | 2025-11-05 | Organic net sales growth | -2.5–-2% | – | – | 24 | |
| FY2025 | 2025-08-06 | Operating Cash Flow Conversion | ~100% | – | – | 22 | |
| FY2025 | 2025-05-07 | Gross margin (non-GAAP) | ~40% | – | – | 22 | |
| FY2025 | 2025-05-07 | Operating margin | ~15% | -26.4 | 22 | ||
| FY2025 | 2025-05-07 | Free Cash Flow as a Percentage of Net Sales | ~6% | – | – | 22 | |
| FY2025 | 2025-05-07 | Net Leverage | ~3.5 | – | – | 22 | |
| FY2025 | 2025-05-07 | Annual run-rate potential savings | 150–200 | – | – | 19 | |
| FY2025 | 2025-05-07 | Operating cash flow conversion to adjusted net income | ~100% | – | – | 20 | |
| FY2024 | 2024-11-06 | Revenue growth (YoY) | -5–-3% | -6.1 | 16 | ||
| FY2024 | 2024-08-02 | Organic net sales growth | -3–-1% | – | – | 16 | |
| FY2024 | 2024-05-07 | Revenue | flat | 4,373.4 | – | 12 | |
| FY2024 | 2024-02-27 | EPS (non-GAAP) | 2.5–2.65 | 2.57 | 16 | ||
| FY2023 | 2023-11-07 | EPS (non-GAAP) | 2.5–2.6 | 2.58 | 8 | ||
| FY2023 | 2023-11-07 | Revenue growth (YoY) | -6–4% | – | – | 8 | |
| FY2023 | 2023-11-07 | Organic net sales growth | -3–1% | – | – | 8 |
Perrigo Company Stock: Price & Chart
Chart and key figure trend of Perrigo Company stock: the TradingView chart starts only on click, the key figure chart comes from the core tables up to Q2 2026. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Perrigo Company Event Timeline
What happened at Perrigo Company since 2023: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology
2026 · 9 events
Full-year 2026 outlook reaffirmed with expectation of sequentially stronger second-half performance driven by more favorable category comparisons and continued operational execution 31
CEO Patrick Lockwood-Taylor resigned June 7, 2026; Albert Manzone appointed Interim President and CEO 30
Dermacosmetics Business sold April 30, 2026, generating approximately $359 million in net proceeds applied toward debt reduction 31
Operating income turned positive for the first time after 2 negative periods (-372.3 to +USD 23.5 million). 30
Net income turned positive for the first time after 2 negative periods (-398.6 to +USD 74.5 million). 30
EBITDA turned positive for the first time after 2 negative periods (-289.0 to +USD 119.4 million). 30
“We are maintaining our full-year guidance, supported by clear, quantifiable factors expected to drive improvement in the second half of the year. We recognize that the environment is dynamic, and we are monitoring potential impacts related to geopolitical developments in the Middle East and retailer inventory destocking. Against this backdrop, we are well-positioned to deliver on our 2026 outlook while building a foundation for long-term growth.”
Operating loss of USD 372.3 million primarily due to $330.8 million goodwill impairment on Women's Health, Infant Formula, and Oral Care units following segment reorganization 28
Net sales declined 7.2% to USD 969.2 million, driven by lower consumption and reduced seasonal cough and cold incidence 28
Reporting structure transitioned from geographic Americas/International segments to product category-based reporting (Self Care, Specialty Care, Infant Formula) in Q1 2026 28
2025 · 14 events
“Fiscal year 2025 was a pivotal year for Perrigo. Despite soft category consumption and a challenging Infant Formula end-market, we gained share across store brands and in key brands as our team executed with discipline. These results reinforce the strength of our consumer-preferred portfolio, deep retail partnerships and sharpened focus on everyday consumer health. Our 'Three‑S plan' is delivering meaningful progress in stabilizing our business, streamlining our complexity and strengthening what is working, supported by cost savings program benefits and the implementation of our new commercial operating model.”
Goodwill impairment of $1.3B across Consumer Self-Care Americas ($917.1M) and Consumer Self-Care International ($407.1M), triggered by sustained share price decline and lower infant formula cash flow expectations, drove reported operating loss of USD 1,287.2 million in Q4 2025 25
Operational Enhancement Program launched targeting $80M–$100M gross pre-tax annualized savings by end of FY2027, including approximately 7% workforce reduction 26
Segment reorganization effective January 1, 2026, transitioning from two reporting segments to four segments aligned to the new commercial operating model 26
“While OTC consumption was increasingly soft in the third quarter, the Perrigo team delivered strong in-market performance. We gained dollar, unit and volume share in five of seven store brand categories and grew share in our key brands, a clear sign that consumers are choosing Perrigo products at the shelf. This performance, despite a challenging backdrop, reflects the strength of our Three-S plan (Stabilize, Streamline, Strengthen) and our commitment to delivering trusted, accessible health solutions across multiple price points.”
Full-year 2025 outlook downgraded: reported net sales growth -2.5% to -3.0%, adjusted EPS $2.70 to $2.80, citing infant formula industry dynamics and soft OTC consumption trends 24
Strategic review of infant formula business initiated November 5, 2025, assessing alternatives including reassessing the $240M investment commitment 23
Master Sale and Purchase Agreement signed with Kairos (KKR affiliate) July 13, 2025 to sell ACO Hud Nordic AB and Dermacosmetics Business; transferred to Karo Healthcare AB August 27, 2025 23
Net income turned positive for the first time after 5 negative periods (-8.4 to +USD 7.5 million). 23
“Our second quarter results reflect the continued execution by the global Perrigo team against our Three-S strategic plan. Despite a challenging consumer environment in the U.S. and EU, our diversified portfolio–spanning more molecules at more price points–continues to provide resilience and stability. Our upgraded brand building capabilities are generating positive results as our store brands and key brands are gaining share in their respective markets–demonstrating the strength of our diversified business even amid soft seasonal consumption trends in certain segments, such as allergy, sun care and blister care.”
Adjusted gross margin for consolidated continuing operations decreased 250 basis points to 38.1%, reflecting production variability in infant formula and lower plant overhead absorption 22
Sale of Richard Bittner Business AG to HBI Health & Beauty Innovations Limited completed April 11, 2025 21
One Perrigo growth model scaled across organization effective July 1, 2025; Roberto Khoury appointed EVP Chief Commercial Officer with responsibility for both segments 21
Operating cash flow reached USD 75.9 million vs USD 9.5 million in 2024-Q2 (×8.0). 21
“Investments and innovations to Strengthen the business through our 'High-Grow' brands remain on track to derive benefits in 2026. Collectively, the team delivered meaningful adjusted EPS growth and margin expansion versus the prior year.”
Operating income of USD 46.9 million vs. operating loss of $55.2M in Q1 2024 (source-stated: up 185.0% 19), driven by infant formula recovery and strong upper respiratory sales
Adjusted gross margin expanded 440 basis points to 41.0%, driven by infant formula business recovery and Supply Chain Reinvention benefits 20
Full-year 2025 reported net sales growth guidance widened to 0%–3% from 1%–3% and organic growth to 1.5%–4.5% from 2.5%–4.5%, citing macroeconomic uncertainty 20
2024 · 12 events
“Though 2024 was a challenging year as we had to quickly overcome evolving regulatory dynamics within our infant formula business, we made substantial progress to rewire Perrigo through stabilizing our CSCA businesses, streamlining our operations and strengthening the Company for the long-term.”
Adjusted operating income increased 16.0% in Q4 2024 and adjusted diluted EPS rose 8.1% to 0.93 per share 17
Infant formula net sales grew 17% in Q4 driven by market share gains and recovering customer inventory levels; CSCA nutrition category net sales increased 14.8% 17
FDA reclassified Perrigo's Wisconsin infant formula facility from Voluntary Action Indicated to No Action Indicated status following an October-November 2024 inspection 17
“During the third quarter, we made significant progress to advance our One Perrigo vision by stabilizing core businesses, investing in World-Class CPG capabilities and leadership, and executing with excellence against our accretive initiatives.”
Operating income turned positive at USD 80.4 million after two consecutive quarters of operating losses; adjusted diluted EPS increased 26.6% to 0.81 16
Infant formula business revenue grew 3% year-over-year and 58% sequentially in Q3, with market share gains; Women's Health revenue increased 70.9% driven by Opill and feminine hygiene products 16
Definitive agreement signed September 14, 2024 to sell Orion Laboratories Hospital & Specialty Business; transaction completed November 1, 2024 15
“We are currently making significant progress in quality control, production, packaging and release attainment. We are increasingly confident in the second half profit recovery of this business, which in addition to improved mix and lower variable expenses, are expected to offset lower seasonal demand in the first half of the year and lower distribution in U.S. store brand in the second half of the year. This leads us to reaffirm our 2024 adjusted EPS outlook.”
Net sales of USD 1,065.5 million declined 10.7% year-over-year, with organic net sales down 9.1% primarily due to lower infant formula sales and seasonal demand weakness in Upper Respiratory and Pain & Sleep Aids 14
Full-year 2024 organic net sales growth outlook reduced to -3% to -1% from prior +1% to +3%; adjusted diluted EPS outlook reaffirmed at $2.50-$2.65 14
Sale of HRA Pharma Rare Diseases business to Esteve Healthcare completed July 10, 2024, with $205 million in upfront proceeds received post-quarter end 14
“During the first quarter, we continued to progress our blueprint to build One Perrigo by implementing Project Energize, a growth and efficiency program, as we further align to create sustainable, value accretive growth.”
Net sales of USD 1,082.1 million declined 8.4% year-over-year, driven by organic decline of 7.0% primarily from infant formula volume reductions and SKU prioritization actions 12
Perrigo launched Project Energize, a three-year global investment and efficiency program targeting annualized pre-tax savings of $140-$170 million by 2026 12
Perrigo launched Opill, the first OTC oral contraceptive in the U.S., at more than 65,000 retail stores nationwide 11
2023 · 14 events
“During 2023, we made meaningful progress on our blueprint to build One Perrigo by advancing analyses of portfolio configuration, investment and operations. We are working towards establishing sustainable, value accretive growth through a blended-branded business model that will position us to win in self-care. To accelerate One Perrigo, we are implementing an investment and efficiency program called Project Energize. This program is designed to consumerize, simplify and scale our organization, driving the next evolution of global capabilities and organizational agility.”
$90.0 million goodwill impairment charge on the HRA Rare Diseases reporting unit recorded in Q4 2023, resulting in a reported operating loss for the quarter 10
FY2024 outlook issued with organic net sales growth of 1.0%-3.0% and adjusted diluted EPS range of $2.50-$2.65 10
“I have immersed myself in all facets of our global business since becoming CEO four months ago and remain excited about our opportunities ahead. We have created a 'One Perrigo' blueprint that will guide us to build an operating model where our portfolio, operating systems and behaviors will be simplified, standardized and scaled. This will position us to win in self-care through the creation of a sustainable and value accretive growth engine that will drive Perrigo for the long-term.”
FDA warning letter received August 30, 2023 for Perrigo's Wisconsin infant formula facility; the company was working with the FDA to resolve the issues raised 7
Adjusted gross margin expanded 300 basis points to 39.5% in Q3, driven by strategic pricing, SKU prioritization, and higher margin new products 8
FY2023 organic growth outlook lowered to 1.0%-3.0% and reported growth to 4.0%-6.0% due to infant formula volatility and currency impacts; adjusted EPS range narrowed to $2.50-$2.60 8
Operating cash flow reached USD 124.7 million vs USD 59.2 million in 2022-Q3 (×2.1). 108
“Our second quarter earnings results reflect the dedication and hard work of the entire Perrigo team, who also continued to make meaningful progress against key operational initiatives, including our Supply Chain Reinvention Program, and integrating and synergizing both the HRA and infant formula acquisitions.”
Adjusted gross margin expanded 220 basis points year-over-year to 38.7%, driven by higher margin acquisitions, strategic pricing actions, and SKU prioritization benefits 6
Full-year 2023 adjusted diluted EPS guidance of $2.50-$2.70 and organic net sales growth of 3.0%-6.0% reaffirmed 6
“Perrigo's first quarter results were tremendous. The Company once again delivered double-digit top line growth, and 36% adjusted EPS growth. Importantly, adjusted gross margin expanded by 400 basis points driven nearly equally by the Perrigo base business and benefits from recent acquisitions. Consumer demand was strong across our global portfolio, and, except in categories where we are capacity constrained, Perrigo gained market share globally.”
Voluntary recall initiated for specific infant formula brand manufactured January 2-18, 2023, in response to FDA microbiologic safety guidance 3
Consolidated net sales grew 10.0% to 1,181.7 million; organic net sales increased 6.4% 3 4
Three-year Optimize and Accelerate strategy announced, including Supply Chain Reinvention Program targeting annual run-rate savings of $200-300 million by end of fiscal 2028 3
Operating income more than doubled YoY (21.7 to USD 48.5 million, +124%). 3
Perrigo Company Business Model
The Perrigo Company business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology
Perrigo is a consumer self-care company that develops, manufactures, and markets over-the-counter health and wellness products, primarily under store brand (private label) and licensed brand formats. Its revenue is organized across three reporting segments: Self Care, covering analgesics, cough, cold, allergy, and gastrointestinal OTC categories; Specialty Care, covering women's health, oral care, and dermatology; and Infant Formula, comprising store brand and branded baby formula. Perrigo earns revenue principally by supplying major retail chains and pharmacies, leveraging its manufacturing scale and private-label expertise to compete on cost and shelf presence across multiple product categories.
Perrigo Company Stock: Share-Price Drivers
Factors Perrigo Company itself names as material for its business development, reproduced neutrally, without price forecast and without assessment of our own. NadirAlpha methodology
The new structure re-cuts how demand and profitability are read across the portfolio, with Self Care the largest category at USD 1,022.8 million total group net sales context and women's-health and infant-formula lines carried inside it 25 29
Perrigo reported Self Care net sales of 543.0 in 2026-Q1 with the source stating a decline of 11.5% year on year 29
Perrigo's Specialty Care net sales were 207.0 in 2026-Q1, with the source stating growth of 4.0% 29
Perrigo's Infant Formula net sales were 90.0 in 2026-Q1, with the source stating growth of 2.1%, extending earlier market-share gains 29 16
Perrigo cited continued momentum of its Opill over-the-counter oral contraceptive and the ellaOne product in the second quarter, with ellaOne noted as a launch 31 29
Perrigo is running Project Energize alongside a newly initiated Operational Enhancement Program and a Nutrition Network Optimization project aimed at cost and margin, lifting adjusted operating income to USD 125 million against a low reported operating result 30 22
Sector trend: Perrigo's consumer self-care KPIs point to softer top-line demand in the core Self Care category while women's health and specialty lines grow, and management's change flags show decelerating growth with confirmed guidance 29 30.
Perrigo Company Revenue by Type (as of 2026-Q2 · USD million · 10/11)
Revenue of Perrigo Company split by segment or product type exactly as the company itself reports it; segment totals can deviate from group revenue. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|
| Period 2026-Q1 (3M) | |||||
| Self Care | 2025-Q1 | 543 | -11.5% | – | 29 |
| Specialty Care | 2025-Q1 | 207 | 4% | – | 29 |
| All Other | 2025-Q1 | 129.2 | – | 24.7% | 28 |
| Infant Formula | 2025-Q1 | 90 | 2.1% | – | 29 |
| Period FY2025 (12M) | |||||
| Consumer Self-Care Americas | 2022-Q3 | 2,585.3 | -4% | – | 26 |
| Consumer Self-Care International | 2022-Q3 | 1,667.7 | -0.7% | – | 26 |
| Period 2025-H1 (3M) | |||||
| Digestive Health | 2024-Q3 | 109.7 | 12.9% | – | 22 |
| Nutrition | 2024-Q3 | 95.6 | 10.9% | – | 22 |
| VMS and Other CSCA | 2024-Q3 | 3.1 | 42.9% | – | 22 |
| Digestive Health and Other CSCI | 2023-Q4 | 26.8 | 40.9% | – | 22 |
| Period FY2023 (12M) | |||||
| Total CSCI Net Sales | 2023-Q4 | 1,693.3 | 11% | – | 10 |
Perrigo Company Products & announcements (11/37 active+recent)
37 product announcements of Perrigo Company since 2023, grouped by year; active means still mentioned in the most recent reports, nothing is deleted. NadirAlpha methodology
Status: LaunchedPlannedStable
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2026 | |||
| Opill product momentum continuation (3x) | 2026-03 | 29 | |
| 2025 | |||
| Operational Enhancement Program | 2025-10 | 30 | |
| New product launches in Q3 2025 | 2025-09 | 24 | |
| TriosTM program launch in CSCA | 2025 | 25 | |
| Phenylephrine No Drip Nasal Spray | 2025 | 25 | |
| NiQuitin® flavor roll outs | 2025 | 25 | |
| Nasalmer® new geographic area launches | 2025 | 25 | |
| Jungle Formula® franchise products | 2025 | 25 | |
| IBU/APAP Dual Active | 2025 | 25 | |
| Compeed® franchise products (3×) | 2025 | 25 | |
| Bronchostop® 5 in1 CSCI line extensions | 2025 | 25 | |
| 2024 | |||
| Infant formula market share gains | 2024-09 | 16 | |
| Opill brand launch (2×) | 2024-06 | 13 | |
| Project Energize initiated | 2024-03 | 9 | |
| Opill women's health product (3×) | 2024-03 | 20 | |
| Opill OTC birth control pill launch (2×) | 2024-03 | 12 | |
| Opill (progestin-only daily oral contraceptive) | 2024-03 | 9 | |
| Opill (first-ever over-the-counter oral contraceptive) | 2024-03 | 11 | |
| New product launches including Opill in U.S. | 2024 | 16 | |
| Compeed Spots launch | 2024 | 18 | |
| 2023 | |||
| Store brand Ibuprofen 125mg Tablets launch | 2023-12 | 10 | |
| Store brand Dual Action Acetaminophen 250mg launch | 2023-12 | 10 | |
| Store brand Cough Relief Liquid Honey launch | 2023-12 | 10 | |
| Polyethylene Glycol 3350 Orange | 2023-12 | 10 | |
| Omeprazole Mini Capsules | 2023-12 | 10 | |
| Opill OTC approval | 2023-07 | 5 | |
| Opill | 2023-07 | 19 | |
| Opill daily oral contraceptive OTC application review | 2023-05 | 3 | |
| Voluntary recall of OTC product in CSCA business | 2023-03 | 4 | |
| Voluntary infant formula product recall | 2023-03 | 4 | |
| Omeprazole Cool Mint | 2023-03 | 4 | |
| Nasonex 24HR | 2023-03 | 4 | |
| Acetaminophen and Ibuprofen Tablets ANDA approval | 2023-03 | 3 | |
| Opill pre-launch investments | 2023 | 8 | |
| Nicotine Ice Mint Lozenge (3x) | 2023 | 18 | |
| Compeed Stops product brand | 2023 | 9 | |
| Acetaminophen and Ibuprofen Dual Action product | 2023 | 9 | |
Perrigo Company Transactions & Events (24)
Transactions of Perrigo Company since 2023: acquisitions, disposals, agreements and regulation, deliberately including smaller items; purchase prices only when the company names them. NadirAlpha methodology
Acquisitions by Perrigo Company
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Segment Reorganization to Category-Based Structure | 2026-01 | Completed | 25 |
| 2025 | |||
| Nutrition Network Optimization project | 2025 | Completed | 30 |
| 2024 | |||
| GoodStart infant formula brand integration | 2024-12 | Completed | 17 |
| Project Energize Efficiency Program (2x) | 2024-03 | Completed | 10 |
| 2023 | |||
| Rare Diseases reporting unit impairment | 2023-12 | Completed | 9 |
| HRA Pharma brands acquisition (Mederma, Compeed, ella) | 2023-12 | Completed | 10 |
| 2022 | |||
| Gateway acquisition | 2022-10 | Completed | 10 |
| Gateway infant formula plant acquisition (5×) | 2022-04 | Completed | 10 |
| HRA Pharma acquisition (3×) | 2022 | Completed | 18 |
Divestitures and exits by Perrigo Company
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Dermacosmetics branded business divestiture | 2026-06 | Divested | 26 |
| Dermacosmetics Business sale | 2026-04 | Divested | 30 |
| Dermacosmetics Business Divestiture | 2026-03 | Divested | 31 |
| 2025 | |||
| ACO Hud Nordic AB and Dermacosmetics Business (2×) | 2025-07 | Divested | 23 |
| Richard Bittner Business AG (2×) | 2025-04 | Divested | 25 |
| Oral Care Business Strategic Review | 2025 | Divested | 31 |
| Infant formula business strategic review | 2025 | Divested | 31 |
| 2024 | |||
| Divestiture of Rare Diseases reporting unit, Hospital and Specialty Business and branded asset sales in CSCI (2×) | 2024-12 | Divested | 22 |
| Sale of Hospital and Specialty Business (5×) | 2024 | Divested | 17 |
| Sale of 7 branded products in 4 separate transactions | 2024 | Divested | 18 |
| HRA Rare Diseases business (7×) | 2024 | Divested | 17 |
| 2022 | |||
| ScarAway brand divestiture (4×) | 2022-03 | Divested | 10 |
| 2021 | |||
| Rx segment divestiture | 2021 | Divested | 9 |
| Rx business divestiture | 2021 | Divested | 7 |
Partnerships and contracts of Perrigo Company
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2024 | |||
| Dr. Brown's Baby partnership for infant formula (2×) | 2024-09 | Agreement | 18 |
Perrigo Company Risks (81 since the annual report of 2026-02-26, 224 tracked in total)
NadirAlpha lists 81 active risks of Perrigo Company from the filings, the category as a coloured dot with legend, the wording as a short summary of the filing with no assessment of our own. NadirAlpha methodology
Category: MacroLegalCustomersCompetitionFinancialSupply chainTechnologyGeopoliticsMarketRegulatoryPeopleStrategyCyberESG
| Risk | Category | Last reported |
|---|---|---|
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2026-08-05 (2026-Q2), source 31 | ||
| Ongoing category softness and uncertain consumer and macroeconomic environment impacting demand. | = | |
| Exposure to U.S. and foreign tariffs, with changes in global trade relations creating price pressures. | = | |
| Pending litigation could have material adverse impact on operating results, cash flows, and liquidity. | = | |
| Perrigo Company: first mention in 10-Q quarterly report of 2026-08-05 (2026-Q2), source 30 | ||
| Heightened competition from existing and new entrants in infant formula market. | = | |
| Lost distribution of Good Start brand hindered recovery of market share. | = | |
| Rising interest rates impact debt servicing costs. | = | |
| Persistent inflationary pressures in food, energy, labor, and materials. | = | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2026-02-26 (FY2025), source 26 | ||
| Significant uncertainty regarding scope, timing, and implementation of tariff policies. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2025-08-06 (2025-Q2), source 21 | ||
| Wisconsin facility FDA warning letter August 2023; additional inspection observations November 2023. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2025-05-07 (2025-Q1), source 19 | ||
| Ongoing conflict affects suppliers in Israel for raw materials and finished goods. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2024-11-06 (2024-Q3), source 16 | ||
| Need to refinance outstanding debt at maturity with uncertainty on timing, amount, and cost. | 2026-Q2 2026-08-05 31 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2024-08-02 (2024-Q2), source 14 | ||
| Operation Stork Speed regulatory initiative introduces new compliance obligations. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 10-K annual report of 2024-02-27 (FY2023), source 9 | ||
| Potential pricing pressures from customers and reliance on retail distribution channels. | 2026-Q2 2026-08-05 31 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2024-02-27 (2023-Q4), source 10 | ||
| Supply chain impacts from armed conflict, trade sanctions, and disease outbreaks affecting business operations. | 2026-Q2 2026-08-05 31 | |
| Potential costs and reputational impact of product recalls or sales halts. | 2026-Q2 2026-08-05 31 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2023-08-08 (2023-Q2), source 6 | ||
| Uncertainty regarding ability to obtain and maintain regulatory approvals for products and operations. | 2026-Q2 2026-08-05 31 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2023-08-08 (2023-Q2), source 5 | ||
| Inflation, interest rates, currency volatility, tariffs, and trade restrictions pose ongoing challenges. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2023-05-09 (2023-Q1), source 4 | ||
| War in Ukraine negatively impacts operations in region; potential for material escalation. | 2026-Q2 2026-08-05 30 | |
| Commodity disruptions from climate impacts, Russia-Ukraine conflict, Middle East tensions. | 2026-Q2 2026-08-05 30 | |
| Competition from industry participants with greater marketing resources or larger market shares. | 2026-Q2 2026-08-05 31 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2023-05-09 (2023-Q1), source 3 | ||
| Translation and transaction exposure to Euro and British Pound Sterling fluctuations. | 2026-Q2 2026-08-05 30 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2026-05-06 (2026-Q1), source 29 | ||
| Lower seasonal incidence of cough and cold versus prior year pressures sales | = | |
| Retailer inventory destocking creating sales headwinds | = | |
| Receipt of works council and regulatory approval for Dermacosmetics transaction uncertain | = | |
| Increased or new tariffs and changes in global trade relations affect costs | = | |
| Perrigo Company: first mention in 10-Q quarterly report of 2026-05-06 (2026-Q1), source 28 | ||
| Perrigo Wisconsin facility received FDA Form 483 in February 2026 unrelated to production batch recalls | = | |
| FDA Operation Stork Speed initiative expanding testing, labeling, and personal importation rules affecting competitive dynamics | = | |
| Persistent inflationary pressures on labor, energy, and food costs globally with ongoing geopolitical uncertainty | = | |
| Significant volatility and uncertainty regarding scope, timing, and implementation of U.S. tariffs on imported products | = | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2026-02-26 (FY2025), source 26 | ||
| Soft over-the-counter category consumption impacting store brand and key brand sales growth | = | |
| Infant formula market dynamics and soft consumer consumption pressuring volumes and margins | = | |
| Changes in tax structure and recording of U.S. valuation allowance creating $57.2 million and $26.7 million tax charges respectively | = | |
| Requirement to obtain works council and regulatory approval for Dermacosmetics divestiture transaction | = | |
| Perrigo Company: first mention in 10-K annual report of 2026-02-26 (FY2025), source 25 | ||
| Must maintain maximum first lien secured net leverage ratio of 3.00 to 1.00 and minimum interest coverage ratio of 3.00 to 1.00. | = | |
| Loss of significant customers, particularly top ten representing 47% of consolidated net sales | = | |
| U.S. tariffs increased global cost of goods sold by estimated 30-40 million in 2026 with continued uncertainty | = | |
| War in Ukraine and Middle East conflict impacting supply chain and API sourcing from Israel | = | |
| Tariff impacts and inflation increasing global cost of goods sold with continued mitigation efforts | = | |
| Significant changes to leadership team create uncertainty and potential operational disruption | = | |
| Product liability, patent, commercial and regulatory proceedings with $59.0 million loss accrual. | = | |
| Ongoing tax audits and adjustment disputes with U.S. and foreign tax authorities with uncertain outcomes | = | |
| Segment reorganization may result in structural goodwill impairment charges up to $350 million in Q1 2026. | = | |
| Management believes operations and borrowing resources sufficient for capital requirements though risks remain elevated | 2026-Q1 2026-05-06 28 | |
| Ability to execute restructuring and strategic initiatives with personnel changes | 2026-Q1 2026-05-06 29 | |
| Exposure to ransomware, data theft and cyber-attacks on complex IT systems | = | |
| Growing focus on environmental impact and sustainability requirements across product categories | = | |
| Commitment to monitoring and ensuring compliance with human rights standards in supply chain | = | |
| Supply chain disruptions and inflationary pressures from ongoing geopolitical conflicts | = | |
| Limited availability of certain raw materials and single-source supplier dependencies | = | |
| Deteriorating economic conditions could reduce consumer discretionary spending on self-care products | = | |
| Persistent inflationary pressures on labor, commodities and energy with continued impact on cost structure | = | |
| Increasing e-commerce and alternative sales channels putting pressure on pricing and market share | = | |
| Increased scrutiny on pricing practices and antitrust enforcement activity by government agencies | = | |
| Changes to tax laws including OBBBA provisions affecting effective tax rate and cash tax payments | = | |
| Inability to timely leverage emerging technologies including generative AI could impact competitiveness | = | |
| Perrigo Company: first mention in 10-Q quarterly report of 2025-11-05 (2025-Q3), source 23 | ||
| Risk of non-compliance with anti-corruption, anti-bribery and economic sanctions laws | = | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2025-08-06 (2025-H1), source 22 | ||
| Resolution of uncertain tax positions and ongoing litigation adversely affecting results. | = | |
| Perrigo Company: first mention in 10-Q quarterly report of 2025-08-06 (2025-Q2), source 21 | ||
| Risk of sanctions or regulatory penalties for non-compliance with FCPA UK Bribery Act Irish corruption laws internationally | = | |
| Perrigo Company: first mention in 10-K annual report of 2025-02-28 (FY2024), source 18 | ||
| Moody's downgrade to Ba3 from Ba2 increases borrowing costs and affects future capital market access. | FY2025 2026-02-26 25 | |
| Civil False Claims Act investigation by Department of Justice regarding drug pricing and marketing practices | FY2025 2026-02-26 25 | |
| Third-party patent litigation risks for generic product launches and potential damages or licensing requirements | FY2025 2026-02-26 25 | |
| Product contamination risks, recalls and consumer injury claims could damage reputation and financial results | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2024-11-06 (2024-Q3), source 15 | ||
| S&P downgraded issuer rating to B+ from BB- and Fitch outlook adjusted to negative on March 16-31, 2026 | 2026-Q1 2026-05-06 28 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2024-08-02 (2024-Q2), source 13 | ||
| FDA warning letter and Form 483 inspections of Wisconsin infant formula facility requiring corrective actions | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 10-K annual report of 2024-02-27 (FY2023), source 9 | ||
| Significant goodwill impairment charges with ongoing sensitivity to discount rates and perpetual growth estimates | 2026-Q1 2026-05-06 28 | |
| Hazardous substances on current or formerly owned property with investigative and remedial obligations | FY2025 2026-02-26 25 | |
| Senior Secured Credit Facilities contain restrictions limiting operating flexibility and debt incurrence | FY2025 2026-02-26 25 | |
| Multiple drug pricing and antitrust class action lawsuits with potential material adverse impact on reputation and financial position | FY2025 2026-02-26 25 | |
| Failure to protect patents and trade secrets could allow competitors to develop similar products | FY2025 2026-02-26 25 | |
| Potential securities litigation and disclosure matters with material adverse financial impact | FY2025 2026-02-26 25 | |
| Adverse results in pending litigation could harm operating results and cash flows | 2026-Q1 2026-05-06 29 | |
| Supply chain disruptions in agricultural commodities and geopolitical tensions affecting product availability | FY2025 2026-02-26 25 | |
| U.S. dollar devaluation relative to euro and other foreign currencies could impact non-U.S. operating units. | FY2025 2026-02-26 25 | |
| Inflationary increases in product costs and overhead may adversely affect gross margin and operating results. | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2023-11-07 (2023-Q3), source 7 | ||
| FDA Operation Stork Speed and evolving regulatory expectations on infant formula safety and testing | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 8-K-EX99.1 earnings release of 2023-08-08 (2023-Q2), source 6 | ||
| Supply chain impacts from armed conflict, trade sanctions and disease | 2026-Q1 2026-05-06 29 | |
| Third-party patents and intellectual property rights may limit ability to bring new products to market | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2023-08-08 (2023-Q2), source 5 | ||
| 1% increase in interest rates would result in approximately $2.3 million additional annual interest expense. | FY2025 2026-02-26 25 | |
| Perrigo Company: first mention in 10-Q quarterly report of 2023-05-09 (2023-Q1), source 3 | ||
| Russia-Ukraine conflict impacts operations in region with uncertain duration and potential material effects | 2026-Q1 2026-05-06 28 | |
| Irish regulators undertaking formal review of non-prescription codeine products with potential reclassification | FY2025 2026-02-26 25 | |
| Complex regulatory requirements across multiple jurisdictions affecting manufacturing and distribution | FY2025 2026-02-26 25 | |
Perrigo Company Reported KPIs (as disclosed) (275)
NadirAlpha collects 275 reported KPIs of Perrigo Company from the filings up to Q2 2026; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| Perrigo Company, published 2026-08-05, period 2026-Q2 | ||
| Total Debt | 3.3 billion | 31 |
| Net Leverage | approximately 4.0 times | 31 |
| Net Interest Expense | 156 | 31 |
| Net Cash from Operating Activities | 83 | 31 |
| Dividends Paid | 40 | 31 |
| Dermacosmetics Divestiture Proceeds | 359 | 31 |
| Cash and Cash Equivalents | 400 | 31 |
| Capital Expenditures | 14 | 31 |
| Adjusted Effective Tax Rate | 18.0% | 31 |
| Perrigo Company, published 2026-05-06, period 2026-Q1 | ||
| total debt | 3,632.5 | 29 |
| specialty care net sales | 207 | 29 |
| self care net sales | 543 | 29 |
| reported net sales core | 842 | 29 |
| reported net sales all in | 969.2 | 29 |
| net leverage | approximately 4.0 times | 29 |
| infant formula net sales | 90 | 29 |
| dermacosmetics upfront proceeds | €305.6 million | 29 |
| dermacosmetics contingent consideration | €27.0 million | 29 |
| core segment net sales | 840 | 29 |
| cash from operating activities | -113.6 | 29 |
| cash and equivalents | 357.2 | 29 |
| capital expenditures | 13.8 | 29 |
| Term Loan B Facility maturity date | April 20, 2029 | 28 |
| tariff recovery recorded | 21 | 28 |
| Supply Chain Reinvention Program total costs | 286 | 28 |
| Supply Chain Reinvention Program annualized benefits | 157 | 28 |
| Revolving Facility maturity date | March 20, 2031 | 28 |
| Project Energize restructuring charges | 138 | 28 |
| Project Energize reinvestment savings | 35 | 28 |
| Project Energize annualized pre-tax savings | 167 | 28 |
| Operational Enhancement Program expected gross pre-tax annual run rate cost savings low | 80 | 28 |
| Operational Enhancement Program expected gross pre-tax annual run rate cost savings high | 100 | 28 |
| Operational Enhancement Program cash costs low | 80 | 28 |
| Operational Enhancement Program cash costs high | 90 | 28 |
| Infant formula remediation cash costs | 22.6 | 28 |
| Dermacosmetics upfront cash | €305.6 million | 28 |
| Dermacosmetics contingent consideration | €27.0 million | 28 |
| Dermacosmetics Business sale consideration | €332.6 million | 28 |
| Perrigo Company, published 2026-02-26, period FY2025 | ||
| Working capital | 1,043.7 | 25 |
| Total indebtedness | 3.6 billion | 25 |
| Term loan A and B outstanding | 1,394.3 | 25 |
| Tariff cost estimate | 30 million to 40 million | 25 |
| Supply chain reinvention annualized benefits | 157 million | 25 |
| Short-term debt | 36.6 | 25 |
| Richard Bittner Business sale consideration | 14.4 million | 25 |
| Richard Bittner Business impairment | 3.1 million | 25 |
| Project Energize annualized savings | 167 million | 25 |
| Operational Enhancement Program gross cost savings | 80 million to 100 million | 25 |
| Operational Enhancement Program cash costs | 80 million to 90 million | 25 |
| operating cash flow | 238.5 | 25 |
| infant formula remediation costs | 22.6 million | 25 |
| expected 2026 capital expenditures | 90 million to 130 million | 25 |
| dividends per share | 1.16 | 25 |
| dividends paid | 159.3 | 25 |
| cash and cash equivalents | 531.6 | 25 |
| capital expenditures | 93.4 | 25 |
| asset impairments three years | 1,542.0 million | 25 |
| total debt | $3.64 billion | 26 |
| operating cash flow | $239 million | 26 |
| cash and cash equivalents | $532 million | 26 |
| Perrigo Company, published 2025-11-05, period 2025-Q3 | ||
| Working capital | $1,095.3 | 23 |
| total debt | 3.64 billion | 24 |
| reported operating margin | 7.0% | 24 |
| organic operating income growth YTD | +13.2% | 24 |
| organic net sales growth YTD | n/a - declining | 24 |
| operating cash flow YTD | 63 million | 24 |
| net leverage | approximately 3.8x adjusted EBITDA | 24 |
| cash and equivalents | 432 million | 24 |
| cash and cash equivalents | $432.1 | 23 |
| adjusted operating margin | 16.6% | 24 |
| adjusted gross margin | 39.9% | 24 |
| tariffs gross increase to global cost of goods sold full year | approximately $40 million to $50 million | 23 |
| tariffs gross increase to global cost of goods sold 2025 Q4 onwards | approximately $10 million to $20 million | 23 |
| Supply Chain Reinvention Program anticipated costs | between $300 million to $350 million | 23 |
| Supply Chain Reinvention Program anticipated annual run rate savings by end | between $150 million to $200 million | 23 |
| Supply Chain Reinvention Program annual run rate savings opportunity | between $200 million to $300 million | 23 |
| Project Energize restructuring charges | between $140 million to $160 million | 23 |
| Project Energize net reduction of total Perrigo roles | approximately 6% | 23 |
| Project Energize annualized pre-tax savings by end | between $140 million to $170 million | 23 |
| Project Energize annual reinvestment | approximately $40 million to $60 million | 23 |
| Nutrition Network Optimization previously announced investment | $240 million | 23 |
| Infant formula remediation costs incurred in | approximately 95% | 23 |
| Infant formula remediation cash costs | approximately $22.6 million | 23 |
| Perrigo Company, published 2025-08-06, period 2025-Q2 | ||
| Unallocated expenses | 58.9 | 21 |
| Unallocated expenses | 115.5 | 21 |
| Tariff impact full year | 50-60 million | 21 |
| Tariff impact | 10-20 million | 21 |
| Supply Chain Reinvention Program savings by end of | 150-200 million | 21 |
| Supply Chain Reinvention Program estimated costs | 300-350 million | 21 |
| Supply Chain Reinvention Program annual run rate potential savings | 200-300 million | 21 |
| Project Energize role reduction | 6% | 21 |
| Project Energize restructuring charges | 140-160 million | 21 |
| Project Energize annualized pre-tax savings | 140-170 million | 21 |
| Project Energize annual reinvestment | 40-60 million | 21 |
| Obligor group total revenues | 1,481.9 | 21 |
| Obligor group operating loss | (51.6) | 21 |
| Obligor group net loss | (307.7) | 21 |
| Obligor group gross profit | 423.0 | 21 |
| Nutrition Network Optimization investment | 240 million | 21 |
| Non-current liabilities obligor group | 11,835.8 | 21 |
| Non-current assets obligor group | 4,242.6 | 21 |
| Infant formula remediation cash costs to date | 22.6 million | 21 |
| Due to non-guarantors | 7,713.4 | 21 |
| Current liabilities obligor group | 827.4 | 21 |
| Current assets obligor group | 1,830.4 | 21 |
| CSCI Womens Health | 41.1 | 21 |
| CSCI VMS | 38.6 | 21 |
| CSCI Skin Care | 122.9 | 21 |
| CSCI Pain and Sleep Aids | 63.5 | 21 |
| CSCI Oral Care | 25.2 | 21 |
| CSCI Healthy Lifestyle | 60.7 | 21 |
| CSCA Womens Health | 18.7 | 21 |
| CSCA Skin Care | 57.8 | 21 |
| CSCA Pain and Sleep Aids | 80.2 | 21 |
| CSCA Oral Care | 60.0 | 21 |
| CSCA Nutrition | 95.6 | 21 |
| CSCA Healthy Lifestyle | 73.7 | 21 |
| CSCA Digestive Health | 109.7 | 21 |
| Perrigo Company, published 2025-08-06, period 2025-H1 | ||
| total debt | $3.65 billion | 22 |
| Operating cash flow H1 | $11 million | 22 |
| Net sales Q2 | $1,056.3 million | 22 |
| Net sales H1 | $2,100.2 million | 22 |
| Dividends paid H1 | $80 million | 22 |
| cash and equivalents | $454.2 million | 22 |
| Capital expenditures H1 | $45 million | 22 |
| Adjusted operating margin Q2 | 12.8% | 22 |
| Adjusted operating margin H1 | 13.4% | 22 |
| Adjusted gross margin Q2 | 38.1% | 22 |
| Adjusted gross margin H1 | 39.5% | 22 |
| Perrigo Company, published 2025-05-07, period 2025-Q1 | ||
| total debt | $3.63 billion | 20 |
| Term Loan A Facility and Term Loan B Facility outstanding | 1420.4 | 19 |
| Short-term debt | 36.2 | 19 |
| Project Energize restructuring charges incurred to date | $111 million | 20 |
| Project Energize annualized savings achieved to date | approximately $159 million | 20 |
| Project Energize annualized pre-tax savings | $140 million to $170 million | 20 |
| Operating income percentage | 4.5% | 19 |
| Nutrition Network Optimization investment planned | 240 | 19 |
| Lease liabilities | 190.4 | 19 |
| Lease assets | 181.3 | 19 |
| Infant formula remediation cash costs to date | 22.6 | 19 |
| Infant formula business recovery | 16% net sales growth in Nutrition category | 20 |
| Global brands organic growth (excluding retailer stocking benefit from Opill launch) | +5.9% | 20 |
| Effective tax rate | 99.0% | 19 |
| cash and cash equivalents | $410 million | 20 |
| CSCI Operating income percentage | 9.4% | 19 |
| CSCA Operating income percentage | 10.3% | 19 |
| Adjusted operating margin expansion | 550 basis points | 20 |
| Adjusted gross margin expansion | 440 basis points | 20 |
| Perrigo Company, published 2025-02-28, period FY2024 | ||
| Working capital | $915.3 million | 18 |
| Total indebtedness | $3.6 billion | 18 |
| Net valuation allowance increase | 47.7 | 18 |
| Loss accrual for litigation contingencies | 76.8 | 18 |
| Liabilities for uncertain tax positions | 309.8 | 18 |
| Funded deferred compensation and benefits | 36.7 | 18 |
| dividends per share | $1.10 | 18 |
| dividends paid | $152.5 million | 18 |
| Cumulative net currency translation adjustments | 196.0 | 18 |
| cash from operating activities | $362.9 million | 18 |
| Cash, cash equivalents, restricted cash | $558.8 million | 18 |
| Capital expenditures | $118.3 million | 18 |
| Anticipated capital expenditures | between $120 million and $160 million | 18 |
| Additional annual interest expense 1pct rate increase | 2.3 | 18 |
| Perrigo Company, published 2025-02-27, period 2024-Q4 | ||
| Total Debt | 3.62 | 17 |
| Organic Net Sales Growth (Q4) | 0.7% | 17 |
| Organic Net Sales Growth (FY2024) | -4.5% | 17 |
| Infant Formula Net Sales Growth (Q4) | 17% | 17 |
| Cash from Operating Activities (FY2024) | 363 | 17 |
| Cash conversion | 102.5% | 17 |
| Cash and Cash Equivalents | 559 | 17 |
| Capital Expenditures (FY2024) | 118 | 17 |
| Adjusted operating margin | 17.0% | 17 |
| Adjusted gross margin | 37.2% | 17 |
| Perrigo Company, published 2024-11-06, period 2024-Q3 | ||
| total debt | $4.8 billion | 16 |
| Operating margin reported | 7.4% | 16 |
| Operating margin adjusted | 16.8% | 16 |
| Operating income (9M) | (1.3) | 15 |
| Operating income % (9M) | 0 | 15 |
| Operating income % | 7.4 | 15 |
| Operating income | 80.4 | 15 |
| Operating cash flow conversion guidance | approximately 90% to 100% | 16 |
| Net sales (9M) | 3,235.1 | 15 |
| Net sales | 1,087.5 | 15 |
| Interest expense guidance | approximately $180 million | 16 |
| Gross margin reported | 37.2% | 16 |
| Gross margin adjusted | 41.0% | 16 |
| cash and cash equivalents | $1.5 billion | 16 |
| Adjusted tax rate guidance | 19% to 20% | 16 |
| Perrigo Company, published 2024-08-02, period 2024-Q2 | ||
| total debt | $4.1 billion | 14 |
| operating cash flow | $10 million | 14 |
| dividends paid | $38 million | 14 |
| cash and equivalents | $543 million | 14 |
| capital expenditures | $29 million | 14 |
| adjusted operating margin | 13.1% | 14 |
| adjusted gross margin | 40.6% | 14 |
| Working capital | 1128.2 | 13 |
| Term Loan A and Term Loan B outstanding | 1838.6 | 13 |
| Short-term debt | 440.8 | 13 |
| Project Energize gross savings YTD | approximately $53 million | 14 |
| Other expense (income), net | 3.4 | 13 |
| Net cash from operating activities | 8.1 | 13 |
| Net cash for investing activities | -96.8 | 13 |
| Net cash for financing activities | -110.2 | 13 |
| Lease liabilities | 207.7 | 13 |
| Lease assets | 202.9 | 13 |
| Interest expense, net | 44.1 | 13 |
| Infant formula YoY impact | 20.8 (in millions, except per share amounts) | 14 |
| Cash, cash equivalents and restricted cash | 542.8 | 13 |
| Adjusted operating margin | 13.1% | 14 |
| Adjusted gross margin | 40.6% | 14 |
| Perrigo Company, published 2024-05-07, period 2024-Q1 | ||
| Working capital | 1,034.0 | 11 |
| total debt | 4.1 billion | 12 |
| Term Loan A and Term Loan B outstanding | 1,848.3 | 11 |
| Short-term debt | 440.6 | 11 |
| Operating cash flow conversion | 90%-100% | 12 |
| Lease liabilities | 194.0 | 11 |
| Lease assets | 190.1 | 11 |
| Interest expense | approximately 180 million | 12 |
| Cash, cash equivalents and restricted cash | 658.5 | 11 |
| cash and cash equivalents | 659 million | 12 |
| Perrigo Company, published 2024-02-27, period FY2023 | ||
| Working capital | $935.9 | 9 |
| Walmart customer concentration | 11.8% | 9 |
| Total indebtedness | $4.1 billion | 9 |
| Top ten customers concentration | 46% | 9 |
| Manufacturing facilities | 17 manufacturing plants | 9 |
| HRA Pharma acquisition price USD | approximately 1.9 billion | 9 |
| HRA Pharma acquisition price EUR | 1.8 billion | 9 |
| Countries of operation | 33 countries | 9 |
| Collective agreement coverage | approximately 20% | 9 |
| Codeine sales Ireland | approximately 18 million | 9 |
| Cash equivalents and restricted cash | $751.3 | 9 |
| capital expenditures | $101.7 | 9 |
| asset impairments three years | 263.1 million | 9 |
| Perrigo Company, published 2024-02-27, period 2023-Q4 | ||
| total debt | 4 billion | 10 |
| Operating cash flow conversion | 115% | 10 |
| Net cash from operating activities | 208.6 | 10 |
| Net cash from operating activities | 405.5 | 10 |
| Cash on balance sheet | 751 million | 10 |
| Cash conversion | 178% | 10 |
| Cash conversion | 115% | 10 |
| Adjusted gross margin | 39.8% | 10 |
| Adjusted gross margin | 38.4% | 10 |
| Adjusted gross margin | 38.8% | 10 |
| Adjusted gross margin | 36.2% | 10 |
| Adjusted gross margin | 50.0% | 10 |
| Adjusted gross margin | 51.8% | 10 |
| Adjusted gross margin | 52.1% | 10 |
| Adjusted gross margin | 51.6% | 10 |
| Adjusted gross margin | 34.1% | 10 |
| Adjusted gross margin | 31.6% | 10 |
| Adjusted gross margin | 31.3% | 10 |
| Adjusted gross margin | 28.2% | 10 |
| Perrigo Company, published 2023-11-07, period 2023-Q3 | ||
| Operating cash flow conversion | 143% | 8 |
| Operating cash flow | 196.8 | 8 |
| Cash conversion | 143% | 8 |
| cash and cash equivalents | 598.3 | 8 |
| Perrigo Company, published 2023-08-08, period 2023-Q2 | ||
| Working capital | $1,199.3 | 5 |
| Unallocated expenses (three months) | $49.7 | 5 |
| Unallocated expenses (six months) | $105.6 | 5 |
| Unallocated expenses (prior year | $94.7 | 5 |
| Unallocated expenses (prior year | $167.7 | 5 |
| Total Revenues (obligor group) | $1,666.8 | 5 |
| Revenue from non-guarantors | $51.8 | 5 |
| Other (income) expense to non-guarantors | $(95.8) | 5 |
| Organic net sales growth | 0.8% | 6 |
| Operating cash flow | 53 million | 6 |
| Operating Income (loss) (obligor group) | $2.0 | 5 |
| Due to non-guarantors | $6,399.5 | 5 |
| Constant currency net sales growth | 6.6% | 6 |
| cash and cash equivalents | 555 million | 6 |
| Perrigo Company, published 2023-05-09, period 2023-Q1 | ||
| Ukraine operating income | $1 million | 3 |
| Ukraine net sales | $3 million | 3 |
| Ukraine gross profit | $2 million | 3 |
| Interest expense | approximately 180 million | 4 |
| Cash conversion ratio | approximately 100% | 4 |
| Adjusted tax expense rate | approximately 21.5% | 4 |
Perrigo Company Development
The business development of Perrigo Company period by period up to Q2 2026, each text from the original report of that period, source numbers lead to the source. NadirAlpha methodology
FY2026: Perrigo Company
Perrigo reported declining net sales across both quarters of the first half of fiscal 2026, with Q1 net sales of USD 969.2 million falling 7.2% year-over-year 28 and Q2 net sales of USD 1,022.8 million declining 3.2% versus the prior-year period 30, reflecting lower consumption and reduced seasonal incidence of cough and cold products 29. In Q1, the company recorded a $330.8 million goodwill impairment charge across its Women's Health, Infant Formula, and Oral Care reporting units following a segment reorganization to product category-based reporting, resulting in an operating loss of USD 372.3 million 28. Perrigo completed the sale of its Dermacosmetics Business on April 30, 2026, generating approximately $359 million in net proceeds applied toward debt reduction 31. CEO Patrick Lockwood-Taylor resigned in June 2026 and Albert Manzone was appointed Interim President and CEO 30, while Perrigo reaffirmed its full-year 2026 outlook with expectation of sequentially stronger second-half performance 31.
FY2025: Perrigo Company
Perrigo's full-year 2025 net sales were 4,253.1 million, a decrease of 2.8% versus the prior year, driven by lower OTC volumes, divested businesses, and the absence of a prior-year Opill stocking benefit, partially offset by favorable currency translation 25. The reported operating result was a loss of 1,122.2 million, compared to income of $112.9 million in 2024, primarily due to goodwill impairment charges of $1.3 billion across the Consumer Self-Care Americas and Consumer Self-Care International segments, reflecting a sustained decrease in share price and lower expected cash flows related to infant formula market dynamics 25. On an adjusted basis, operating income of 622.3 million grew 2.3% 26, and adjusted diluted EPS was 2.75, an increase of 7.0% from $2.57 in 2024, supported by Project Energize savings and lower interest expense 26. The year saw material portfolio actions including the completed divestiture of Richard Bittner Business AG, a signed agreement to sell the Dermacosmetics business for up to €327 million, and initiated strategic reviews of the infant formula and oral care businesses 25. Perrigo reported full-year operating cash flow of 238.5 million and net debt of 75.4 million at year-end 25.
FY2024: Perrigo Company
Perrigo's full-year 2024 consolidated net sales of USD 4,373.4 million declined 6.1% year-over-year, driven by lower OTC volumes, infant formula remediation impacts, and divestitures 17. Perrigo Company posted a full-year net loss of USD 171.8 million and adjusted diluted EPS of 2.57, which decreased 0.4% versus the prior year 17. Project Energize, launched in Q1 2024, delivered approximately $139 million in gross annual savings for the year toward a $140-$170 million annualized target by 2026, and the FDA reclassified Perrigo's Wisconsin infant formula facility to No Action Indicated status following a Q4 inspection 17. Perrigo Company divested its HRA Pharma Rare Diseases business in July 2024 for proceeds of $244.5 million and its Orion Laboratories Hospital & Specialty Business in November 2024 18. Full-year free cash flow was USD 244.6 million and net debt declined to USD -78.8 million by year-end 126.
FY2023: Perrigo Company
Perrigo posted full-year 2023 net sales of 4,655.6 million, a 4.6% increase driven by the Gateway and HRA Pharma acquisitions and strategic pricing actions 9. Reported gross margin expanded 340 basis points to 36.1% while adjusted diluted EPS increased 24.6% to 2.58 9 10. Operating income of 151.9 million reflected a 92.5% year-over-year improvement, although a $90.0 million goodwill impairment charge on the HRA Rare Diseases reporting unit weighed on Q4 reported results 9 10. Operating cash flow reached 405.5 million with a 115% conversion ratio, and net debt ended the year at 77.5 million 10. Key developments included the FDA approval of Opill as the first over-the-counter daily oral contraceptive in the United States, an FDA warning letter for the Wisconsin infant formula facility, and the launch of Project Energize targeting annualized pre-tax savings of $140-170 million by 2026 9 10.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
47 sources on Perrigo Company since 2023; the superscript numbers in the chapters refer to these rows, older documents are in the expandable part. NadirAlpha methodology
Older sources (+16)
| # | Document type | Published |
|---|---|---|
| #201 | 10-Q quarterly report | 2016-05-16 |
| #202 | 10-Q quarterly report | 2016-08-10 |
| #203 | 10-Q quarterly report | 2016-11-10 |
| #204 | 10-K annual report | 2017-05-22 |
| #206 | 10-K annual report | 2017-05-22 |
| #205 | 10-Q quarterly report | 2017-08-10 |
| #208 | 10-K annual report | 2018-03-01 |
| #207 | 10-Q quarterly report | 2018-08-09 |
| #210 | 10-K annual report | 2019-02-27 |
| #209 | 10-Q quarterly report | 2019-08-08 |
| #213 | 10-K annual report | 2020-02-27 |
| #212 | 10-Q quarterly report | 2020-05-05 |
| #211 | 10-Q quarterly report | 2020-08-05 |
| #214 | 10-Q quarterly report | 2021-05-12 |
| #215 | 10-Q quarterly report | 2021-08-11 |
| #216 | 10-Q quarterly report | 2021-11-12 |
Perrigo Company Stock FAQ
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Gross margin (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Perrigo Company report?
As reported for Q2 2026: Total Debt, Net Leverage, Net Interest Expense, Net Cash from Operating Activities, Dividends Paid, Dermacosmetics Divestiture Proceeds. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Self Care, Specialty Care, All Other, Infant Formula.
Does Perrigo Company pay a dividend?
The filings report on the dividend; most recent entry: dividends paid 40 (millions) (2026-Q2) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Perrigo Company?
NadirAlpha links all 47 original filings used (SEC filings) in the sources chapter: earnings release, quarterly report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.